The main purpose of this study is to determine how much MRTX849 can safely be administered to people. This will include looking at what side effects occur and how often they occur.

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. This protocol will allow access to cord blood units that are unlicensed.

The purpose of this study is to examine 4 different therapeutic approaches towards improving the 3 year event free survival from 6% to 35% in newly diagnosed metastatic Rhabdomyosarcoma patients.

The goal of this study is to see if it is feasible to use electronic questionnaires to measure patient related outcomes before, during, and after radiation for gynecologic cancer in a high-volume radiation oncology clinic.

This is a non-interventional, observational study to collect data on survival, quality of life, and other follow-up information on patients who receive GammaTile therapy.

Patients will undergo a blood draw for a gene classifier test. Some patients will have their physicians informed of the result, and another group of patients will be randomized to be managed by standard of care. Qualifying patients have incidentally identified lung nodules assessed as < 50% risk of cancer.

Develop a device to measure patient preferences in the treatment of bladder cancer.

Our team developed a calculator to help oncologists better estimate prognosis in patients with metastatic breast cancer (MBC). Using this information, our team developed a prognostic calculator to predict risk of death within 30 days for patients with MBC. For this information to impact care, it will have to be used in clinical practice. In order to increase the likelihood of successful adoption of the calculator into clinical practice, we will study its implementation and evaluate its impact. In this study, we will seek the input of doctors, nurses, and advance practice providers who care for patients with MBC to better understand the factors that encourage and dissuade discussion of prognosis and use of such a prognostic tool.

To evaluate the safety and efficacy of streamlining Yttrium-90 radioembolization workflow for patients with small Hepatocellular Carcinoma (HCC) (<5cm) that have no aggressive features on baseline imaging.

The purpose of this study is to determine the safety of the addition of universal donor, expanded NK cells to gemcitabine/docetaxel for treatment of relapsed and refractory sarcomas.